Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Omvohwhich is the second new treatment option for UC patients approved this week after Celltrions Zymfentrais the first to selectively target the p19 subunit of IL-23, which plays a role in inflammation related to the condition, according to Lilly
Sourris KC, Ding Y, Maxwell SS, Al-Sharea A, Kantharidis P, Mohan M, Rosado CJ, Penfold SA, Haase C, Xu Y, et al
Antidiabetic Activity FX has promising potential as a therapeutic drug for the treatment of type 2 diabetes and diabetes-related problems
PMID: 24623521
Who Should Choose Tirzepatide: Ideal Candidates: Need maximum weight loss (50+ pounds) Want most effective medication available Can afford $349-$1,069/month depending on option Have BMI 30 (or 27 with comorbidities) Plateaued on semaglutide or other medications No contraindications to GLP-1/GIP agonists Particularly Good For: Significant obesity (BMI 35) Previous weight loss medication failures Those who want best possible results Patients who tolerate GLP-1s well Cost Comparison: Value Analysis: Cost per % Body Weight Lost: Brand-Name Tirzepatide: 22.5% loss at $12,828/year Cost per %: $570 Compounded Tirzepatide (TrimRx): 22.5% loss at $4,188/year Cost per %: $186 Compounded Semaglutide (TrimRx): 14.9% loss at $2,388/year Cost per %: $160 Both compounded options offer excellent value, with semaglutide being slightly more cost-efficient per percentage lost, while tirzepatide produces greater absolute weight loss
US$ 27.60
US$ 26.23
US$ 24.90
US$ 21.78
US$ 28.80
US$ 28.12
US$ 29.86
